Terumo announced that it will terminate its supply agreement for plasma collection devices with a U.S. subsidiary of CSL Behring. As a result, a loss of approximately $610 million is expected, and the full-year outlook will be revised downward.
Terumo announced that it has terminated its supply agreement for plasma collection devices with a U.S. subsidiary of CSL Behring. The background is that some supply sites have indicated an intention to switch to products made by other companies. This is expected to affect the business.
The total loss is expected to be approximately $610 million, including impairment losses. As a result, pressure is expected on cash flow from business activities and financial indicators.
The full-year earnings forecast was revised downward, while adjusted operating profit was left unchanged. Operating profit, however, was cut from the previous forecast of ¥257.5 billion to ¥160.0 billion.
The stated background includes the indication by some supply sites that they intend to switch to products made by other companies.